Cargando…
Apatinib Mesylate Inhibits the Proliferation and Metastasis of Epithelioid Malignant Peritoneal Mesothelioma In Vitro and In Vivo
OBJECTIVE: Malignant peritoneal mesothelioma (MPM) is a rare malignancy with few effective molecular therapies. In this study, we evaluated the anti-tumor activity and safety of apatinib, a vascular endothelial growth factor receptor 2 inhibitor, in MPM in vitro and in vivo. METHODS: We established...
Autores principales: | Yang, Zhi-Ran, Chen, Zhi-Gao, Du, Xue-Mei, Li, Yan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7750508/ https://www.ncbi.nlm.nih.gov/pubmed/33365269 http://dx.doi.org/10.3389/fonc.2020.585079 |
Ejemplares similares
-
Efficacy and Adverse Events of Apatinib Salvage Treatment for Refractory Diffuse Malignant Peritoneal Mesothelioma: A Pilot Study
por: Yang, Zhi-Ran, et al.
Publicado: (2022) -
Establishment and histopathological study of patient-derived xenograft models and primary cell lines of epithelioid malignant peritoneal
mesothelioma
por: Yang, Zhi-Ran, et al.
Publicado: (2021) -
Apatinib mesylate tablet in the treatment of advanced malignant melanoma
por: Yang, Lingge, et al.
Publicado: (2018) -
Primary intrahepatic malignant epithelioid mesothelioma
por: Perysinakis, Iraklis, et al.
Publicado: (2014) -
Clinicopathological characteristics of primary peritoneal epithelioid mesothelioma of clear cell type: A case report
por: Du, Xue-Mei, et al.
Publicado: (2021)